AnaptysBio

ANAB Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$57.68

+1.67% today

52W: $15.40 – $68.39

52W Low: $15.40 Position: 79.8% 52W High: $68.39

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

7.07x

Price-to-Sales

EV/EBITDA

33.79x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.7B

Market Capitalization

Revenue Growth

151.1%

YoY Revenue Growth

Profit Margin

-5.64%

Net profit margin

ROE

-24.49%

Return on Equity

Beta

0.41

Market sensitivity

Short Interest

30.63%

% of float sold short

Avg. Volume

558,944

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

11 analysts

Avg. Price Target

$79.91

+38.54% upside

Target Range

$50.00 – $140.00

About the Company

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 104 Exchange: NMS